RxDoctor Payments Data

Rachel Ayers

Family · Ithaca, NYNPI 1265928436

Payments from drug & device makers

$1,736in general payments, 2019–2025

Across 57 payments — averaging $30.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$759
  • Takeda Pharmaceuticals U.S.A., Inc.$254
  • Braintree Laboratories, Inc.$113
  • Madrigal Pharmaceuticals$102
  • QOL Medical, LLC$78
  • Regeneron Healthcare Solutions, Inc.$77
  • plus $352 from 12 others

What the payments were for

  • Food & beverage$1,736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,736 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$40,195
Medicare patients
241
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide50$48,846
Esomeprazole Magnesium35$5,875
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates94$5,664
Dexlansoprazole DrDexlansoprazole12$4,146
Budesonide DrBudesonide13$3,791
Colesevelam Hcl12$1,467
Famotidine141$1,405
Omeprazole136$1,311
CholestyramineCholestyramine (With Sugar)12$1,041
Pantoprazole Sodium82$779
Hydrocortisone15$621
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl26$423
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl26$270
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl15$151
Ondansetron OdtOndansetron23$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$759$48,84650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →